LINC00506 rs6788616: Prostate Cancer Risk Association
The rs6788616 variant is a single nucleotide polymorphism located within the LINC00506 gene. It has been identified in research as one of many genetic markers used to construct polygenic hazard scores for assessing the risk of developing clinically significant prostate cancer.
What each genotype means
Typical prostate cancer risk
This genotype is considered the baseline or reference state for this variant in many populations. Research identifies this variant as part of a polygenic hazard score model for prostate cancer, but this specific genotype does not independently indicate a high risk. Please consult with a healthcare provider for personalized screening recommendations based on your full clinical and family history.
This is a common genotype found in many global populations, though exact frequencies vary by ancestry.
Potential prostate cancer risk marker
Carrying one copy of the G allele means you possess the variant identified in polygenic hazard score models for prostate cancer. These models use multiple genetic markers to estimate risk, and this variant is one of many contributors. This result is not a diagnosis; please discuss your prostate health and screening options with your clinician.
This heterozygous genotype is observed at varying frequencies across different ancestral groups.
Potential prostate cancer risk marker
Carrying two copies of the G allele means you possess the variant identified in polygenic hazard score models for prostate cancer. Because this variant is used in combination with many others to calculate risk, this genotype alone does not determine your overall health outcome. Please discuss your prostate health and appropriate screening schedules with your doctor.
This genotype is less common than the homozygous reference state in most studied populations.
What is rs6788616?
The rs6788616 variant is a specific change in the DNA sequence, classified as an intronic variant. This means it is located within an intron, a non-coding region of the LINC00506 gene that does not provide direct instructions for building a protein. In the context of modern genomics, intronic variants like rs6788616 are frequently studied because they may influence how genes are regulated or expressed, even if they do not alter the protein structure itself. Researchers identify these variants through genome-wide association studies (GWAS), which compare the DNA of individuals with a specific condition to those without it to find statistical patterns. rs6788616 is one of many variants that have been cataloged for their potential contribution to the complex, polygenic architecture of prostate cancer susceptibility.
The Role of LINC00506
LINC00506 stands for Long Intergenic Non-Coding RNA 00506. Unlike protein-coding genes, which act as blueprints for cellular machinery, long non-coding RNAs (lncRNAs) often function as regulators of gene expression. They can interact with DNA, RNA, or proteins to modulate various biological processes within the cell. While the exact mechanism by which LINC00506 influences prostate cancer risk is still an active area of investigation, its inclusion in polygenic hazard models suggests that variations in this region may be associated with the biological pathways that lead to tumor development. Because lncRNAs are increasingly recognized as key players in cancer biology, researchers continue to study LINC00506 to understand how its expression levels might be altered by genetic variants like rs6788616.
Research and Evidence Strength
The evidence linking rs6788616 to prostate cancer is categorized as moderate and is primarily derived from its role in polygenic hazard scores (PHS). A polygenic hazard score is a mathematical model that combines the effects of hundreds of small-effect genetic variants to estimate an individual's risk of developing a disease or the age at which they might be diagnosed. Studies have shown that including rs6788616 in these models can improve the accuracy of risk stratification for prostate cancer. It is important to note that this variant does not act alone; its clinical relevance is tied to its cumulative effect alongside many other genetic markers. Current research emphasizes that while these scores are promising for population-level risk assessment, they are still being refined for clinical utility and are not yet standard diagnostic tools.
Understanding Your Results
If you encounter this variant in a genetic report, it is essential to understand that it represents a statistical association rather than a medical diagnosis. Genetic risk scores are designed to look at the big picture of inherited susceptibility, but they cannot predict with certainty whether an individual will develop prostate cancer. Many factors, including age, family history, and environmental influences, play significant roles in cancer development. You cannot use this information to make medical decisions on your own. If you are concerned about your prostate cancer risk, the most appropriate step is to discuss your family history and any genetic testing results with a healthcare provider or a genetic counselor. They can help you interpret these findings in the context of your overall health and guide you toward appropriate screening or preventative measures.
How common is this variant?
Specific population frequency data for rs6788616 is not widely documented in standard public databases, as its primary utility is within multi-variant polygenic hazard models.
Frequently asked questions
Does having the rs6788616 variant mean I will get prostate cancer?
No. This variant is only one of many genetic factors that contribute to a polygenic risk score. It does not determine your health outcome, and most people with this variant will not develop prostate cancer.
What is a polygenic hazard score?
A polygenic hazard score is a tool that adds up the small effects of many different genetic variants to estimate your relative risk for a disease. It is used by researchers to identify groups of people who might benefit from earlier or more frequent screening.
Should I get tested for rs6788616?
Genetic testing for specific variants like rs6788616 is generally not recommended for individual clinical decision-making outside of a research context. You should consult with a doctor if you have concerns about your prostate cancer risk.
How can I use this information to lower my risk?
You cannot change your genetic variants. However, you can discuss your overall risk profile, including family history and lifestyle factors, with your physician to determine the best screening schedule for you.
Sources & further reading
Educational information only, last refreshed 11/3/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6788616?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29